Developing oral probiotics from Streptococcus salivarius

Future Microbiology

Volumn 7, Issue 12, 2012, Pages 1355-1371

  Wescombe, Philip A ^a   Hale, John DF ^a   Heng, Nicholas CK ^a   Tagg, John R ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

bacterial interference; bacteriocin; bacteriocin like inhibitory substance; immune stimulation; lantibiotic; megaplasmid; oral microbiota; oral probiotic; Streptococcus salivarius

Indexed keywords

PROBIOTIC AGENT;

BACTERIAL STRAIN; DENTAL CARIES; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; HALITOSIS; HUMAN; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SHELF LIFE; STREPTOCOCCUS SALIVARIUS; STREPTOCOCCUS SALIVARIUS 24SMB; STREPTOCOCCUS SALIVARIUS K12; STREPTOCOCCUS SALIVARIUS M18; STREPTOCOCCUS SALIVARIUS ST3; STREPTOCOCCUS SALIVARIUS T30; THRUSH; UPREGULATION;

BIOLOGICAL THERAPY; CANDIDIASIS, ORAL; DENTAL CARIES; HALITOSIS; HUMANS; OTITIS MEDIA; PROBIOTICS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS; VIRUS DISEASES;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SALIVARIUS;

EID: 84870986739     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.113     Document Type: Review

References (77)

1. Teughels W, Van Essche M, Sliepen I, Quirynen M. Probiotics and oral healthcare. Periodontol 48, 111-147 (2008).
2. Food and Agricultural Organization/WHO. Guidelines for the evaluation of probiotics in food. In: Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. Food and Agricultural Organization, Rome, Italy (2002).
3. Zarco MF, Vess TJ, Ginsburg GS. The oral microbiome in health and disease and the potential impact on personalized dental medicine. Oral Dis. 18, 109-120 (2012).
4. Hansen JN. Nisin as a model food preservative. Crit. Rev. Food Sci. Nutr. 34, 69-93 (1994).
5. Sanders CC, Sanders WE. Enocin: An antibiotic produced by Streptococcus salivarius that may contribute to protection against infections due to Group A Streptococci. J. Infect. Dis. 146, 683-690 (1982).
6. Roos K, Hakansson EG, Holm S. Effect of recolonisation with "interfering" alpha streptococci on recurrences of acute and secretory otitis media in children: Randomised placebo controlled trial. BMJ 322, 210-212 (2001).
7. Hillman JD, Mo J, McDonell E, Cvitkovitch D, Hillman CH. Modification of an effector strain for replacement therapy of dental caries to enable clinical safety trials. J. Appl. Microbiol. 102, 1209-1219 (2007).
8. Balakrishnan M, Simmonds RS, Tagg Jr. Diverse activity spectra of bacteriocin-like inhibitory substances having activity against mutans streptococci. Caries Res. 35, 75-80 (2001).
9. Tong H, Chen W, Merritt J, Qi F, Shi W, Dong X. Streptococcus oligofermentans inhibits Streptococcus mutans through conversion of lactic acid into inhibitory H2O2: A possible counteroffensive strategy for interspecies competition. Mol. Microbiol. 63, 872-880 (2007).
10. Kumar PS, Leys EJ, Bryk JM, Martinez FJ, Moeschberger ML, Griffen AL. Changes in periodontal health status are associated with bacterial community shifts as assessed by quantitative 16S cloning and sequencing. J. Clin. Microbiol. 44, 3665-3673 (2006).
11. Wescombe PA, Heng NCK, Burton JP, Chilcott CN, Tagg Jr. Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics. Future Microbiol. 4, 819-835 (2009).
12. Favier CF, Vaughan EE, De Vos WM, Akkermans AD. Molecular monitoring of succession of bacterial communities in human neonates. Appl. Environ. Microbiol. 68, 219-226 (2002).
13. Park HK, Shim SS, Kim SY et al. Molecular analysis of colonized bacteria in a human newborn infant gut. J. Microbiol. 43, 345-353 (2005).
14. Carlsson J, Grahnen H, Jonsson G, Wikner S. Early establishment of Streptococcus salivarius in the mouths of infants. J. Dent. Res. 49, 415-418 (1970).
15. Wescombe PA, Upton M, Dierksen KP et al. Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Appl. Environ. Microbiol. 72, 1459-1466 (2006).
16. Wescombe PA, Burton JP, Cadieux PA et al. Megaplasmids encode differing combinations of lantibiotics in Streptococcus salivarius. Antonie Van Leeuwenhoek 90, 269-280 (2006).
17. Wescombe PA, Heng NCK, Burton JP, Tagg Jr. Something old and something new: An update on the amazing repertoire of bacteriocins produced by Streptococcus salivarius. Probiot. Antimicrob. Proteins 2, 37-45 (2010).
18. Guglielmetti S, Taverniti V, Minuzzo M et al. Oral bacteria as potential probiotics for the pharyngeal mucosa. Appl. Environ. Microbiol. 76, 3948-3958 (2010).
19. Taverniti V, Minuzzo M, Arioli S et al. In vitro functional and immunomodulatory properties of the Lactobacillus helveticus MIMLh5- Streptococcus salivarius ST3 association that are relevant to the development of a pharyngeal probiotic product. Appl. Environ. Microbiol. 78, 4209-4216 (2012).
20. Ishijima SA, Hayama K, Burton JP et al. Effect of Streptococcus salivarius K12 on the in vitro growth of Candida albicans and its protective effect in an oral candidiasis model. Appl. Environ. Microbiol. 78, 2190-2199 (2012).
21. Chen YY, Weaver CA, Burne RA. Dual functions of Streptococcus salivarius urease. J. Bacteriol. 182, 4667-4669 (2000).
22. Sissons CH, Hancock EM. Urease activity in Streptococcus salivarius at low pH. Arch. Oral Biol. 38, 507-516 (1993).
23. Eifuku H, Yoshimitsu-Narita A, Sato S, Yakushiji T, Inoue M. Production and partial characterization of the extracellular polysaccharides from oral Streptococcus salivarius. Carbohydr. Res. 194, 247-260 (1989).
24. Lawman P, Bleiweis AS. Molecular cloning of the extracellular endodextranase of Streptococcus salivarius. J. Bacteriol. 173, 7423-7428 (1991).
25. Bonifait L, Chandad F, Grenier D. Probiotics for oral health: Myth or reality? J. Can. Dent. Assoc. 75, 585-590 (2009).
26. Franker CK. Mutational loss of susceptibility to mutacin GS-5 in Streptococcus pyogenes: Surface protein in a tolerant variant. Antimicrob. Agents Chemother. 19, 166-169 (1981).
27. Wilson M, Martin R, Walk ST et al. Clinical and laboratory features of Streptococcus salivarius meningitis: A case report and literature review. Clin. Med. Res. 10, 15-25 (2012).
28. Santagati M, Scillato M, Patane F, Aiello C, Stefani S. Bacteriocin-Producing oral streptococci and inhibition of respiratory pathogens. FEMS Immunol. Med. Microbiol. 65, 23-31 (2012).
29. Burton JP, Wescombe PA, Moore CJ, Chilcott CN, Tagg Jr. Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Appl. Environ. Microbiol. 72, 3050-3053 (2006).
30. Heng NCK, Haji-Ishak NS, Kalyan A et al. Genome sequence of the bacteriocin-Producing oral probiotic Streptococcus salivarius strain M18. J. Bacteriol. 193, 6402-6403 (2011).
31. Martin V, Maldonado-Barragan A, Jimenez E, Ruas-Madiedo P, Fernandez L, Rodriguez JM. Complete genome sequence of Streptococcus salivarius PS4, a strain isolated from human milk. J. Bacteriol. 194, 4466-4467 (2012).
32. Guedon E, Delorme C, Pons N et al. Complete genome sequence of the commensal Streptococcus salivarius strain JIM8777. J. Bacteriol. 193, 5024-5025 (2011).
33. Delorme C, Guedon E, Pons N et al. Complete genome sequence of the clinical Streptococcus salivarius strain CCHSS3. J. Bacteriol. 193, 5041-5042 (2011).
34. Geng J, Huang SC, Li S, Hu S, Chen YY. Complete genome sequence of the ureolytic Streptococcus salivarius strain 57.I. J. Bacteriol. 193, 5596-5597 (2011).
35. Burton J, Chilcott C, Wescombe P, Tagg J. Extended safety data for the oral cavity probiotic Streptococcus salivarius K12. Probiot. Antimicrob. Protiens 2, 135-144 (2010).
36. Burton JP, Cowley S, Simon RR, McKinney J, Wescombe PA, Tagg Jr. Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: A randomized, placebo-controlled, double-blind study. Food Chem. Toxicol. 49, 2356-2364 (2011).
37. Tanzer JM, Kurasz AB, Clive J. Inhibition of ecological emergence of mutans streptococci naturally transmitted between rats and consequent caries inhibition by Streptococcus salivarius TOVE-R infection. Infect. Immun. 49, 76-83 (1985).
38. Tanzer JM, Kurasz AB, Clive J. Competitive displacement of mutans streptococci and inhibition of tooth decay by Streptococcus salivarius TOVE-R. Infect. Immun. 48, 44-50 (1985).
39. Teughels W, Newman MG, Coucke W et al. Guiding periodontal pocket recolonization: A proof of concept. J. Dent. Res. 86, 1078-1082 (2007).
40. Crowe CC, Sanders WE Jr, Longley S. Bacterial interference. II. Role of the normal throat flora in prevention of colonization by group A Streptococcus. J. Infect. Dis. 128, 527-532 (1973).
41. Sanders CC, Nelson GE, Sanders WE. Bacterial Interference. IV. Epidemiological determinants of the antagonistic activity of the normal throat flora against group A Streptococci. Infect. Immun. 16, 599-603 (1977).
42. Sanders CC, Sanders WE Jr, Harrowe DJ. Bacterial interference: Effects of oral antibiotics on the normal throat flora and its ability to interfere with group A streptococci. Infect. Immun. 13, 808-812 (1976).
43. Ausschuss für Biologische Arbeitsstoffe. ABAS-UA 4: Einstufung Biologischer Arbeitsstoffein Resolution 135/Herabstufung von Streptococcus salivarius ssp. salivarius K12. Bundesanstalt für Arbeitsschutz und Arbeitsmedizin, Dortmund, Germany (2005).
44. Hyink O, Wescombe PA, Upton M, Ragland N, Burton JP, Tagg Jr. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl. Environ. Microbiol. 73, 1107-1113 (2007).
45. Dierksen KP, Tagg Jr. The influence of indigenous bacteriocin-Producing Streptococcus salivarius on the acquisition of Streptococcus pyogenes by primary school children in Dunedin, New Zealand. In: Streptococci and Streptococcal Diseases Entering the New Millenium. Martin DR, Tagg JR (Eds). Securacopy, Auckland, New Zealand, 81-85 (2000).
46. Fantinato VC, Jorge, AO, Shimizu MT. Production of bacteriocin-like inhibitory substances (BLIS) by Streptococcus salivarius strains isolated from the tongue and throat of children with and without sore throat. Rev. Microbiol. 30, 332-334 (1999).
47. Guglielmetti S, Taverniti V, Minuzzo M et al. Oral bacteria as potential probiotic for the pharyngeal mucosa. Appl. Environ. Microbiol. 76, 3948-3958 (2010).
48. Horz HP, Meinelt A, Houben B, Conrads G. Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-Time quantitative polymerase chain reaction. Oral Microbiol. Immunol. 22, 126-130 (2007).
49. Burton JP, Chilcott CN, Moore CJ, Speiser G, Tagg Jr. A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J. Appl. Microbiol. 100, 754-764 (2006).
50. Kazor CE, Mitchell PM, Lee AM et al. Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. J. Clin. Microbiol. 41, 558-563 (2003).
51. Power DA, Burton JP, Chilcott CN, Dawes PJ, Tagg Jr. Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur. J. Clin. Microbiol. Infect. Dis. 27, 1261-1263 (2008).
52. Holmes AR, Gopal PK, Jenkinson HF. Adherence of Candida albicans to a cell surface polysaccharide receptor on Streptococcus gordonii. Infect. Immun. 63, 1827-1834 (1995).
53. Liljemark WF, Gibbons RJ. Suppression of Candida albicans by human oral streptococci in gnotobiotic mice. Infect. Immun. 8, 846-849 (1973).
54. Nair RG, Anil S, Samaranayake LP. The effect of oral bacteria on Candida albicans germ-Tube formation. APMIS 109, 147-154 (2001).
55. Nair RG, Samaranayake LP. The effect of oral commensal bacteria on candidal adhesion to human buccal epithelial cells in vitro. J. Med. Microbiol.45, 179-185 (1996).
56. Cosseau C, Devine DA, Dullaghan E et al. The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-Microbe homeostasis. Infect. Immun. 76, 4163-4175 (2008).
57. Abt MC, Osborne LC, Monticelli LA et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 37, 158-170 (2012).
58. Chilcott C, Crowley L, Kulkani V, Jack RW, McLellan AD, Tagg J. Elevated levels of interferon gamma in human saliva following ingestion of Streptococcus salivarius K12. Presented at: Joint New Zealand and Australian Microbiological Societies Annual Meeting. Dunedin, New Zealand, 22-25 November 2005.
59. Mostefaoui Y, Bart C, Frenette M, Rouabhia M. Candida albicans and Streptococcus salivarius modulate IL-6, IL-8, and TNF-Alpha expression and secretion by engineered human oral mucosa cells. Cell. Microbiol. 6, 1085-1096 (2004).
60. Wescombe PA, Upton M, Renault P et al. Salivaricin 9, a new lantibiotic produced by Streptococcus salivarius. Microbiology 157, 1290-1299 (2011).
61. Dodd SJ. A Saliva Model to Demonstrate Streptococcus salivarius BLIS Production and Characterisation of Salivaricin MPS. University of Otago, Dunedin, New Zealand (1999).
62. Burton JP, Wescombe PA, Cadieux PA, Tagg Jr. Beneficial microbes for the oral cavity: Time to harness the oral streptococci? Beneficial Microbes 2, 93-101 (2011).
63. Seymour GJ, Gemmell E. Cytokines in periodontal disease: Where to from here? Acta Odontol. Scand. 59, 167-173 (2001).
64. Fisher MA, Borgnakke WS, Taylor GW. Periodontal disease as a risk marker in coronary heart disease and chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 19, 519-526 (2010).
65. Adam E, Jindal M, Seney S et al. Streptococcus salivarius K12 and M18 Probiotics Reduce Periodontal Pathogen-Induced Inflammation (IADR Paper 150126). American Association, Alexandria, VA, USA (2011).
66. Abbot EL, Smith WD, Siou GP et al. Pili mediate specific adhesion of Streptococcus pyogenes to human tonsil and skin. Cell. Microbiol. 9, 1822-1833 (2007).
67. Takashiba S, Naruishi K, Murayama Y. Perspective of cytokine regulation for periodontal treatment: Fibroblast biology. J. Periodontol. 74, 103-110 (2003).
68. De Vrese M, Winkler P, Rautenberg P et al. Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. Vaccine 24, 6670-6674 (2006).
69. Ukena SN, Westendorf AM, Hansen W et al. The host response to the probiotic Escherichia coli strain Nissle 1917: Specific up-regulation of the proinflammatory chemokine MCP-1. BMC Med. Genet. 6, 43 (2005).
70. Kleinberg I. Effect of urea concentration on human plaque pH levels in situ. Arch. Oral. Biol. 12, 1475-1484 (1967).
71. Peterson S, Woodhead J, Crall J. Caries resistance in children with chronic renal failure: Plaque pH, salivary pH, and salivary composition. Pediatric Res. 19, 796-799 (1985).
72. Newberry RD, Stenson WF, Lorenz RG. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat. Med. 5, 900-906 (1999).
73. Wallace JL. COX-2: A pivotal enzyme in mucosal protection and resolution of inflammation. Sci. World J. 6, 577-588 (2006).
74. Tan XD, Chen YH, Liu QP, Gonzalez- Crussi F, Liu XL. Prostanoids mediate the protective effect of trefoil factor 3 in oxidant-induced intestinal epithelial cell injury: Role of cyclooxygenase-2. J. Cell Sci. 113, 2149-2155 (2000).
75. Nelson-Rees WA, Daniels DW, Flandermeyer RR. Cross-contamination of cells in culture. Science 212, 446-452 (1981).
76. Walls T, Power D, Tagg J. Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: Potential to protect against otitis media? J. Med. Microbiol. 52, 829-833 (2003).
77. Tagg JR, Hale JDF, Wescombe PA. BLIS-Producing probiotics targeting the oral cavity. Microbiol. Aust. 33, 103-105 (2012).